We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biochemical Markers Predict Risk of Incident Diabetes

By LabMedica International staff writers
Posted on 22 Aug 2018
Low osteocalcin and C-telopeptide of type 1 collagen levels in postmenopausal women are associated with an increased risk for insulin resistance and incident diabetes.

A recent study investigated the relationship of osteocalcin (OC), which is a marker of bone formation, and C-telopeptide of type I collagen (CTX), which a marker of bone resorption, with incident diabetes in older women.

A multi-institute team of scientists led by those at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, NY, USA) analyzed 1,455 female participants from the population-based Cardiovascular Health Study (mean age 74.6 ± 5.0 years). More...
The cross-sectional association of serum total OC and CTX levels with insulin resistance (HOMA-IR) was examined using multiple linear regressions. The longitudinal association of both markers with incident diabetes, defined by follow-up glucose measurements, medications, and ICD-9 codes, was examined using multivariable Cox proportional hazards models.

The investigators reported that continuous levels of osteocalcin were significantly inversely related to insulin resistance. Continuous C-telopeptide of type 1 collagen levels, though marginally insignificant, showed a similar relationship to insulin resistance. At median follow-up of 11.5 years, 196 cases of incident diabetes were discovered among the participants. After adjustment, both biomarkers still showed inverse associations with incident diabetes (osteocalcin: hazard ratio 0.85 per SD); C-telopeptide of type 1 collagen: hazard ratio 0.82 per SD).

The authors concluded that osteocalcin and C-telopeptide of type 1 collagen are strongly associated with insulin resistance and incident diabetes in late postmenopausal women. The findings also suggest that bone health may be a factor in glucose maintenance in the same postmenopausal demographic. The study was published in the August 2018 issue of the journal Diabetes Care.

Related Links:
Albert Einstein College of Medicine


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.